Woo KT, Choong HL, Wong KS, Tan HK, Foo M, Stephanie FC, Lee EJ, Anantharaman V, Lee GS, Chan CM. A retrospective Aliskiren and Losartan study in non-diabetic chronic kidney disease. World J Nephrol 2013; 2(4): 129-135 [PMID: 24255896 DOI: 10.5527/wjn.v2.i4.129]
Corresponding Author of This Article
Keng-Thye Woo, Professor, Department of Renal Medicine Singapore General Hospital, Outram Road, 169608, Singapore. woo.keng.thye@sgh.com.sg
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Keng-Thye Woo, Hui-Lin Choong, Kok-Seng Wong, Marjorie Foo, Grace SL Lee, Choong-Meng Chan, Han- Kim Tan, Department of Renal Medicine, Singapore General Hospital, 169608, Singapore
Fook-Chong Stephanie, Department of Clinical Research, Singapore General Hospital, 169608, Singapore
Evan JC Lee, Vathsala Anantharaman, Department of Nephrology, National University of Singapore, 169608, Singapore
Author contributions: Woo KT, Main author, coordinated study, recruited patients and preparation of manuscript; Choong HL helped in designing data bases and strategy, recruited patients and helped in writing; Wong KS involved in recruiting and participation in trial and helped in editing paper; Tan HK helped in recruiting, participation of trial , preparation of references and tables; Foo M helped in recruitment of patients and their treatment, preparation of paper; Stephanie FC, Statistician involved in design and analysis of data, writing of relevant part of paper; Lee EJC contributed patients and participated in treatment and follow of patients; Anantharaman V helped to recruit and treat patients, advised on paper; Lee GSL, Co-author and Co ordinator for patient recruitment, helped in editing of paper; Chan CM recruited and treatment of trial patients, editing manuscript.
Supported by Singhealth Cluster with IRB approval, CIRB Ref: 569E
Correspondence to: Keng-Thye Woo, Professor, Department of Renal Medicine Singapore General Hospital, Outram Road, 169608, Singapore. woo.keng.thye@sgh.com.sg
Telephone: +65-63266049 Fax: +65-62202308
Received: May 28, 2013 Revised: August 2, 2013 Accepted: August 28, 2013 Published online: November 6, 2013 Processing time: 160 Days and 1.8 Hours
Core Tip
Core tip: The Aliskiren trial in type 2 diabetes using Cardio-Renal Endpoints (ALTITUDE) study was able to unmask serious adverse events like ischemic heart disease and strokes because it had included Cardio-Renal Endpoints among its primary end points. It may be advisable to require future trials on drugs which could impact on the kidneys, heart and brain to have similar Cardio-Renal Endpoints or Cardio-Neuro-Renal End points to further ensure therapeutic safety of the trial drug. Our modest study compared to the magnitude of the ALTITUDE study still managed to detect the problem of hyperkalaemia in the group treated with Combination therapy with Aliskiren and ARB. Based on our study it would appear that the findings of the ALTITUDE study would also apply to non-diabetic Chronic Kidney Disease patients.
